Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial

医学 偏头痛 安慰剂 急性偏头痛 内科学 麻醉 物理疗法 替代医学 病理
作者
Richard B. Lipton,David W. Dodick,Jessica Ailani,Kaifeng Lu,Michelle Finnegan,Armin Szegedi,Joel M. Trugman
出处
期刊:JAMA [American Medical Association]
卷期号:322 (19): 1887-1887 被引量:291
标识
DOI:10.1001/jama.2019.16711
摘要

Importance: Ubrogepant is an oral calcitonin gene-related peptide receptor antagonist under investigation for acute treatment of migraine. Objective: To evaluate the efficacy and tolerability of ubrogepant compared with placebo for acute treatment of a single migraine attack. Design, Setting, and Participants: Phase 3, multicenter, randomized, double-blind, placebo-controlled, single-attack, clinical trial (ACHIEVE II) conducted in the United States (99 primary care and research clinics; August 26, 2016-February 26, 2018). Participants were adults with migraine with or without aura experiencing 2 to 8 migraine attacks per month. Interventions: Ubrogepant 50 mg (n = 562), ubrogepant 25 mg (n = 561), or placebo (n = 563) for a migraine attack of moderate or severe pain intensity. Main Outcomes and Measures: Co-primary efficacy outcomes were pain freedom and absence of the participant-designated most bothersome migraine-associated symptom (among photophobia, phonophobia, and nausea) at 2 hours after taking the medication. Results: Among 1686 randomized participants, 1465 received study treatment (safety population; mean age, 41.5 years; 90% female); 1355 of 1465 (92.5%) were evaluable for efficacy. Pain freedom at 2 hours was reported by 101 of 464 participants (21.8%) in the ubrogepant 50-mg group, 90 of 435 (20.7%) in the ubrogepant 25-mg group, and 65 of 456 (14.3%) in the placebo group (absolute difference for 50 mg vs placebo, 7.5%; 95% CI, 2.6%-12.5%; P = .01; 25 mg vs placebo, 6.4%; 95% CI, 1.5%-11.5%; P = .03). Absence of the most bothersome associated symptom at 2 hours was reported by 180 of 463 participants (38.9%) in the ubrogepant 50-mg group, 148 of 434 (34.1%) in the ubrogepant 25-mg group, and 125 of 456 (27.4%) in the placebo group (absolute difference for 50 mg vs placebo, 11.5%; 95% CI, 5.4%-17.5%; P = .01; 25 mg vs placebo, 6.7%; 95% CI, 0.6%-12.7%; P = .07). The most common adverse events within 48 hours of any dose were nausea (50 mg, 10 of 488 [2.0%]; 25 mg, 12 of 478 [2.5%]; and placebo, 10 of 499 [2.0%]) and dizziness (50 mg, 7 of 488 [1.4%]; 25 mg, 10 of 478 [2.1%]; placebo, 8 of 499 [1.6%]). Conclusions and Relevance: Among adults with migraine, acute treatment with ubrogepant compared with placebo led to significantly greater rates of pain freedom at 2 hours with 50-mg and 25-mg doses, and absence of the most bothersome migraine-associated symptom at 2 hours only with the 50-mg dose. Further research is needed to assess the effectiveness of ubrogepant against other acute treatments for migraine and to evaluate the long-term safety of ubrogepant among unselected patient populations. Trial Registration: ClinicalTrials.gov Identifier: NCT02867709.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
苗苗完成签到,获得积分10
1秒前
后来者完成签到 ,获得积分10
1秒前
重要的强炫完成签到,获得积分10
2秒前
2秒前
过过过完成签到 ,获得积分10
3秒前
哈哈完成签到,获得积分10
3秒前
开朗的天佑完成签到,获得积分10
4秒前
erlangenbio发布了新的文献求助10
4秒前
甜蜜板栗完成签到 ,获得积分10
5秒前
科研通AI2S的应助被害怕的慕晴采纳,获得10
5秒前
6秒前
6秒前
7秒前
归帆关注了科研通微信公众号
8秒前
8秒前
9秒前
粒橙酱完成签到,获得积分10
10秒前
马亚斌发布了新的文献求助10
10秒前
庾楼月宛如昨完成签到 ,获得积分10
11秒前
12秒前
12秒前
杜欣悦发布了新的文献求助10
13秒前
13秒前
多看点文献吧完成签到,获得积分10
13秒前
思源的应助被nxdr采纳,获得10
14秒前
冯梦梦完成签到,获得积分10
15秒前
之子之远完成签到,获得积分10
15秒前
传奇3的应助被MADAO采纳,获得30
17秒前
大白完成签到 ,获得积分10
17秒前
CITY111119发布了新的文献求助10
17秒前
17秒前
17秒前
zww113发布了新的文献求助10
17秒前
18秒前
冯梦梦发布了新的文献求助10
18秒前
童童完成签到,获得积分10
19秒前
19秒前
7ian完成签到 ,获得积分10
20秒前
欢喜夏天完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621